Related references
Note: Only part of the references are listed.Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Katja Weisel et al.
CLINICAL DRUG INVESTIGATION (2022)
Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study
Maria-Victoria Mateos et al.
BLOOD (2021)
How to choose a time zero for patients in external control arms
Daniel Backenroth
PHARMACEUTICAL STATISTICS (2021)
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry
Maximilian Merz et al.
CANCERS (2021)
UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
SZ Usmani et al.
Hematology Transfusion and Cell Therapy (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
Balancing Covariates via Propensity Score Weighting
Fan Li et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2018)
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available
Miguel A. Hernan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)
Current treatment landscape for relapsed and/or refractory multiple myeloma
Meletios A. Dimopoulos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool
Georgia Salanti
RESEARCH SYNTHESIS METHODS (2012)
Doubly Robust Estimation of Causal Effects
Michele Jonsson Funk et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2011)
A basic introduction to fixed-effect and random-effects models for meta-analysis
Michael Borenstein et al.
RESEARCH SYNTHESIS METHODS (2010)
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Peter C. Austin
STATISTICS IN MEDICINE (2009)
Share Paper
